-
公开(公告)号：EP4424684A1
公开(公告)日：2024-09-04
申请号：EP22886066.4
申请日：2022-10-27
发明人： FU, Xiangyu , DING, Charles Z. , HU, Lihong
IPC分类号： C07D471/20 , A61K31/438 , A61P35/00
CPC分类号： C07D471/20 , A61K31/438 , A61P35/00
摘要： ABSTRACT
Disclosed are a pyrrolopyrazole spiro compound, and the use thereof in preparing a drug for treating related diseases. The present invention specifically relates to a compound as represented by formula (I'), and a stereoisomer and a pharmaceutically acceptable salt thereof.-
公开(公告)号：EP4406971A1
公开(公告)日：2024-07-31
申请号：EP22872081.9
申请日：2022-09-23
发明人： LU, Zhenzhen , WANG, Yujie , ZHANG, Zhengping , XU, Hongjiang , ZHAO, Wei
摘要： Provided are an anti-CD40 antibody and a use thereof, such as a mouse, human, chimeric, or humanized antibody specifically binding to CD40, and an antigen-binding fragment thereof, and further provided are a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, and an expression vector and a host cell for expressing the antibody or the antigen-binding fragment thereof. Further provided are a preparation method and a use method for the antibody or the antigen-binding fragment thereof, comprising treating and preventing immune diseases.
-
公开(公告)号：EP4393506A1
公开(公告)日：2024-07-03
申请号：EP22860563.0
申请日：2022-08-25
发明人： CHENG, Yanju , LI, Yingchun , KONG, Lingjie , GUO, Xiaolu , ZHAO, Wei
摘要： The present disclosure provides a pharmaceutical composition of an anti-IL4R antibody and a use thereof. The pharmaceutical composition comprises the anti-IL4R antibody or an antigen binding fragment thereof, and a buffering agent; and the pharmaceutical composition can further comprise a surfactant and a stabilizer.
-
4.发明公开
公开(公告)号：EP4374875A1
公开(公告)日：2024-05-29
申请号：EP22845446.8
申请日：2022-07-22
发明人： LUO, Suxia , LI, Ning , MA, Yijie , BIE, Liangyu , LI, Jiajun
IPC分类号： A61K39/395 , A61K31/4709 , A61P35/00
CPC分类号： A61K39/395 , A61P35/00 , A61K31/4709
摘要： A combination drug for treatment of gastric carcinoma and/or esophagogastric junction cancer, comprising an anti-PD-L1 antibody and anlotinib or a pharmaceutically acceptable salt thereof. The combination drug further comprises at least one third therapeutic agent. In addition, the present application further provides a use of a combination drug or a pharmaceutic composition, which comprises an anti-PD-L1 antibody and anlotinib or a pharmaceutically acceptable salt thereof, in preparation of a drug for treatment of gastric carcinoma and/or esophagogastric junction cancer.
-
公开(公告)号：EP3967702B1
公开(公告)日：2024-03-20
申请号：EP20805780.2
申请日：2020-05-09
发明人： LIU, Yingchun , XU, Zhaobing , HU, Lihong , DING, Charles Z. , ZHU, Xingxun , CHEN, Shuhui
IPC分类号： C07K5/062 , C07D403/06 , A61K31/4045 , A61P35/00 , A61K38/00
-
6.发明授权
公开(公告)号：EP3674307B1
公开(公告)日：2023-06-07
申请号：EP18849368.8
申请日：2018-08-23
发明人： DAI, Liguang , DUAN, Xiaowei , YANG, Yanqing , LIU, Xijie , LI, Hongjuan , ZHAO, Na , SUN, Yinghui , KONG, Fansheng , ZHANG, Jiuqing , ZHU, Yizhong , YANG, Ling , LIU, Fei
IPC分类号： C07D498/22 , C07D487/04 , A61K31/519 , C07D519/00 , A61P29/00
-
公开(公告)号：EP3305292B1
公开(公告)日：2022-09-14
申请号：EP16799359.1
申请日：2016-05-27
发明人： HE, Xiongxiong , DONG, Ping , CAI, Jiahui , LU, Xifeng , XU, Jiao , JIANG, Bo , DENG, Zhenxue , SUI, Shanshan
IPC分类号： A61K31/4355 , A61K9/14 , A61K9/20 , A61K9/48 , A61P35/00 , C07D491/048
-
公开(公告)号：EP3400942B1
公开(公告)日：2022-04-13
申请号：EP17735839.7
申请日：2017-01-06
发明人： WANG, Xunqiang , YANG, Ling , XU, Zhongnan , WANG, Xiangjian , GENG, Wenjun
IPC分类号： A61K31/4709 , A61P35/00
-
公开(公告)号：EP3434676B1
公开(公告)日：2022-03-09
申请号：EP17769492.4
申请日：2017-03-27
发明人： WANG, Shulong , CHEN, Kuncheng , LIU, Xijie , HU, Yuandong , LIU, Bo , PENG, Yong , LUO, Hong , HAN, Yongxin , WANG, Shanchun , LIU, Mei , XU, Hongjiang
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00 , A61P35/02
-
公开(公告)号：EP3505516B1
公开(公告)日：2021-10-06
申请号：EP17842961.9
申请日：2017-08-24
发明人： TANG, Song , ZHU, Yizhong , LIU, Fei , ZHOU, Jie , CHEN, Zhilin , XU, Hongjiang , TIAN, Xin
IPC分类号： C07D401/12 , C07C57/145 , C07C51/41 , A61K31/517 , A61P35/00
-
-
-
-
-
-
-
-
-
搜索结果
161 条记录 (耗时 0.025 秒)
